Skip to main content

Advertisement

Table 3 Risk factors in total population, in group with and without cardiac complications

From: Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients

Risk factor Total population Group with cardiac complications Group with no cardiac complications Value of p no complications vs complications
  N = 100 N = 38 N = 62  
Age (years) 46 47 45 0.96
Overweight 38% 12 (31.57%) 26 (41.93%) 0.61
obesity 35% 16 (42.10%) 19 (30.64%) 0.57
Hypertension 11% 4 (10.52%) 7 (11.29%) 0.88
Diabetes 7% 3 (7.89%) 4 (6.45%) 0.31
LVFE baseline 70% 74% 67% < 0.001
Chemotherapy with or without anthracycline 100% Sequential 25 (65.5%) Sequential 35 (56.5%) 0.3
anthracycline 13 (34.5%) anthracycline 27 (43.5%)
Nb of anthracycline cycles 4 4 4 0.61
Concomitant radiotherapy with trastuzumab 69 24 (63%) 45 (72%) 0.318